Chief Financial Officer
Chris Sullivan serves as Chief Financial Officer at Avalo Therapeutics, Inc., overseeing financial strategy during the company's advancement of its IL-1β pipeline, including the Phase 2 LOTUS trial for AVTX-009. His role supports the clinical-stage biotech's growth amid key appointments and trial pr